Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study finds fulvestrant promising therapy for hormone receptor-positive disease
June 2nd, 2005
According to published research from England, "Fulvestrant (Faslodex) is a new type of estrogen receptor (ER) antagonist that binds, blocks, and degrades the ER, leading to reduced expression of the progesterone receptor (PgR). "Unlike the selective ER modulator tamoxifen, fulvestrant is devoid of any known agonist activity." N. Bundred, University of South Manchester Hospital, explained, "Fulvestrant has a steroidal structure that competitively binds to the ER with an affinity much greater than that of tamoxifen. After binding to fulvestrant, degradation of the ER is accelerated, ultimately resulting in a reduction in cellular ER. ...
Source: Women's Health Weekly (2005-06-02)
|
